• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

SAVOR-TIMI 53 study: saxagliptin had better glucose control than placebo but no cardiovascular benefit

  • in Cardiovascular
  • — 22 Sep, 2013

AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in type II diabetes but has failed to show a benefit in terms of cardiovascular outcomes. At the European Society of Cardiology Annual Congress Dr Deepak Bhatt MD, Professor of Medicine at Harvard Medical School and Chief of Cardiology, VA Boston Healthcare System Brigham and Women’s Hospital explains that this agent should be a useful addition in second and third line treatment.

You may also like...

  • Audio Journal of Cardiovascular Medicine: May 2006 – In the company of James Tcheng Audio Journal of Cardiovascular Medicine: May 2006 – In the company of James Tcheng 21 May, 2006
  • Better Criteria For Cardiac Resynchronisation Needed in Heart Failure: PROSPECT Trial Results Better Criteria For Cardiac Resynchronisation Needed in Heart Failure: PROSPECT Trial Results 5 Sep, 2007
  • Bivalirudin For Angioplasty: Expensive Heparin? Bivalirudin For Angioplasty: Expensive Heparin? 30 Apr, 2008
  • Blood Pressure, Cholesterol, Smoking: Key Factors in New European Guidelines to Prevent Heart Disease Blood Pressure, Cholesterol, Smoking: Key Factors in New European Guidelines to Prevent Heart Disease 5 Sep, 2007

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Novel oral anticoagulants: latest opinion from the ESC congress
  • Next story AudioMedica.com with MDFM: Novel oral anticoagulants: latest opinion from the ESC congress
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • COVID-19 Co-Morbidity Risks Quantified from Three…
    • Pembrolizumab: No Survival Gains Second Line In…
    • New Front Line Standard for Older Patients with…
  • Home
  • Cardiovascular
  • SAVOR-TIMI 53 study: saxagliptin had better glucose control than placebo but no cardiovascular benefit

© COPYRIGHT 2020 AUDIOMEDICA.COM.